ReviewInfluenza and other respiratory viruses2017
Influenza antivirals currently in late-phase clinical trial.
Review in Influenza and other respiratory viruses, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 138 citations in OpenAlex.
- Review
- Insights Into monoclonal antibodies and vaccines targeting respiratory viruses.Frontiers in pediatrics · 2026Review
- Global Research Trends on Major Pathogenic Enteric Viruses (1990-2024): A Bibliometric Analysis of Epidemiology, Transmission, and Public Health Impact.Pathogens (Basel, Switzerland) · 2025Review
- Review
- Next-generation vaccines for influenza B virus: advancements and challenges.Archives of virology · 2025Review
- Broadly neutralizing monoclonal antibodies against influenza A viruses: current insights and future directions.Frontiers in microbiology · 2025Review
- Current perspectives on vaccines and therapeutics for Lassa Fever.Virology journal · 2024Review
- Viral sepsis: diagnosis, clinical features, pathogenesis, and clinical considerations.Military Medical Research · 2024Review
- Biological function of sialic acid and sialylation in human health and disease.Cell death discovery · 2024Review
- Article
- Identification of potential antiviral compounds from Egyptian sea stars against seasonal influenza A/H1N1 virus.Journal, genetic engineering & biotechnology · 2024Article
- Outlining recent updates on influenza therapeutics and vaccines: A comprehensive review.Vaccine: X · 2024Review
- Natural History of Influenza B Virus-Current Knowledge on Treatment, Resistance and Therapeutic Options.Current issues in molecular biology · 2023Review
- Structural Investigations of Interactions between the Influenza a Virus NS1 and Host Cellular Proteins.Viruses · 2023Review
- Antiviral polysaccharide and antiviral peptide delivering nanomaterials for prevention and treatment of SARS-CoV-2 caused COVID-19 and other viral diseases.Journal of controlled release : official journal of the Controlled Release Society · 2023Review
- MEK inhibitors as novel host-targeted antivirals with a dual-benefit mode of action against hyperinflammatory respiratory viral diseases.Current opinion in virology · 2023Review
- A Comparison of Etiology, Pathogenesis, Vaccinal and Antiviral Drug Development between Influenza and COVID-19.International journal of molecular sciences · 2023Review
- Drug Cocktail Formulation via Circuit Design.IEEE transactions on molecular, biological, and multi-scale communications · 2023Article
- Switching Heavy Chain Constant Domains Denatures the Paratope 3D Architecture of Influenza Monoclonal Antibodies.Pathogens (Basel, Switzerland) · 2022Article
- Drug update - Baloxavir marboxil: Latest entrant into the arena of pharmacotherapy of influenza.Medical journal, Armed Forces India · 2022Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza antiviral drugs are important for the control of influenza, most specifically for the treatment of influenza patients with severe disease following infection with a seasonal influenza virus, a newly emerging influenza strain, or in the event of a pandemic. Many influenza antivirals that are currently under investigation in late-stage clinical trials differ in their mechanism of action compared to drugs currently licensed for the treatment of influenza. Nitazoxanide and DAS181 target components of the host cell and alter the ability of the virus to replicate efficiently, while small molecule drugs such as T705, JNJ63623872 and S-033188 bind to the viral polymerase complex and restrict viral replication. Monoclonal antibodies that are currently in clinical trial for the treatment of influenza most commonly are targeted to the stem region of the haemagglutinin molecule. Early findings from animal models and in vitro studies suggest that many of the new antiviral drugs when tested in combination with oseltamivir have improved effectiveness over monotherapy. Clinical trials assessing both monotherapy and combination therapy are currently under investigation. It is hoped that as new antivirals are licensed, they will improve the standard of care and outcomes for influenza patients with severe disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.